🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  2. TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Ology Bioservices Ireland LTD

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  4. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 3 small molecule completed

    5 trials

  5. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Pharma Mar S.A.

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  6. Xofigo 1100 kBq/mL solution for injection

    Cancer Prevention Pharma (Ireland) Limited

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Cancer Prevention Pharma (Ireland) Limited

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  8. ZYTIGA 250 mg tablets, ZYTIGA 500 mg film-coated tablets, Apalutamide placebo, JNJ-56021927, PREDNISONE, -

    Pharma Mar S.A.

    Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  9. custirsen sodium

    Teva Pharma GmbH

    Castrate-Resistant Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  10. placebo ketamine inj prep, KETAMINE RENAUDIN 10 mg/ml, solution injectable

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

  11. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  12. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  13. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  14. -, PREDNISONE, PARACETAMOL , FLUDROCORTISONE , ABIRATERONE , -, HYDROCORTISONE, -, Ifinatamab Deruxtecan, -, -, HYDROCORTISONE, HYDROCORTISONE, Opevesostat, DOCETAXEL , ENZALUTAMIDE , PREDNISOLONE

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  15. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  16. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  17. A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

    Incyte Biosciences Distribution B.V.

    Ovarian Cancer

    phase 2 other active

    1 trial

  18. A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 other active

    1 trial

  19. ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy

    phase 2 small molecule active

    1 trial

  20. AV-101

    Vistagen Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  21. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  22. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  23. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  24. AZD5069

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources